--- title: "Autolus Therapeutics (AUTL) news: layoffs" url: "https://aibio.space/companies/autolus-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AUTL layoffs news: Autolus Therapeutics cuts about 13% of staff, targets $15 million in annual savings." --- AUTL Autolus Therapeutics plc NASDAQ · United Kingdom # Autolus Therapeutics (AUTL) news AUTL layoffs news Debt Financing · 2026-08-03 ## [Autolus issues first $75 million under up to $250 million Perceptive facility](https://aibio.space/news/autolus-issues-first-75-million-under-up-250-million-perceptive/) Autolus issued an initial $75 million of notes to Perceptive Advisors on July 30, 2026 under a five-year, interest-only credit facility of up to $250 million. The company's outlook for cash into the second quarter of 2028 counts the first two tranches totaling $100 million. ## Latest Autolus Therapeutics news 1. 2026-08-03 Financings [Autolus issues $75.0 million of notes under up to $250.0 million Perceptive facility](https://aibio.space/news/autolus-issues-75-0-million-notes-under-up-250-0-million-perceptive/) The senior secured notes mature July 30, 2031. Perceptive also received a warrant for up to 3,500,000 American Depositary Shares at $1.9314 each. 2. 2026-04-29 Distress [Autolus Therapeutics to cut about 13% of workforce, expects about $8 million in charges](https://aibio.space/news/autolus-therapeutics-cut-about-13-percent-workforce-expects-about-8/) Autolus will cut about 13% of its workforce and expects about $8 million in severance and related charges, with savings of about $15 million a year from 2027. It reiterated 2026 AUCATZYL revenue guidance of $120 million to $135 million, while its 10-K reports a 2025 net loss of $287.5 million and cash used in operations of $283.6 million. 3. 2026-04-29 Distress [Autolus Therapeutics cuts about 13% of staff, targets $15 million in annual savings](https://aibio.space/news/autolus-therapeutics-cuts-about-13-percent-staff-targets-15-million/) The company expects about $8 million in restructuring charges and continues to expect its cash to fund operations into the fourth quarter of 2027. ## Autolus Therapeutics at a glance - **Ticker**: AUTL - **Listing**: NASDAQ - **Country**: United Kingdom - **Cash, Jun 30, 2026**: $201.6 million ### Related companies - [Kiniksa Pharmaceuticals International](https://aibio.space/companies/kiniksa-pharmaceuticals-international/) NASDAQ: KNSA - [Roivant Sciences](https://aibio.space/companies/roivant-sciences/) NASDAQ: ROIV - [GSK](https://aibio.space/companies/gsk/) LSE: GSK - [Shield Therapeutics Plc](https://aibio.space/companies/shield-therapeutics/) LSE: STX - [Biodexa Pharmaceuticals](https://aibio.space/companies/biodexa-pharmaceuticals/) NASDAQ: BDRX - [Venture Life Group Plc](https://aibio.space/companies/venture-life/) LSE: VLG - [AstraZeneca](https://aibio.space/companies/astrazeneca/) LSE: AZN - [Arecor Therapeutics](https://aibio.space/companies/arecor-therapeutics/) LSE: AREC ### Also on NASDAQ - [Apyx Medical](https://aibio.space/companies/apyx-medical/) APYX - [NEOGEN CORP](https://aibio.space/companies/neogen/) NEOG - [Liquidia](https://aibio.space/companies/liquidia/) LQDA - [PolyPid](https://aibio.space/companies/polypid/) PYPD - [Nuwellis](https://aibio.space/companies/nuwellis/) NUWE - [Maze Therapeutics](https://aibio.space/companies/maze-therapeutics/) MAZE ## Autolus Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | | [$10.1 million](https://www.sec.gov/Archives/edgar/data/1730463/000173046325000019/) | | Research and development | [$117.7 million](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/) | [$138.4 million](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/) | | Net income (loss) | [-$287.5 million](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/) | [-$220.7 million](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/) | | Cash from operations | [-$283.6 million](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/) | [-$206.3 million](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/) | | Cash and equivalents | [$104.1 million](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000123/) | [$227.4 million](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/) | | Short-term investments | [$196.6 million](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000123/) | [$360.6 million](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000038/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $171.4 million, plus short-term investments of $30.2 million, $201.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Autolus Therapeutics Has Autolus Therapeutics cut staff? Our latest story on this, dated Apr 29, 2026: "Autolus Therapeutics cuts about 13% of staff, targets $15 million in annual savings". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/autolus-therapeutics-cuts-about-13-percent-staff-targets-15-million/). What is the ticker symbol of Autolus Therapeutics? Autolus Therapeutics plc trades under the ticker AUTL on NASDAQ. Where is Autolus Therapeutics listed? Autolus Therapeutics plc is listed on NASDAQ. What is the SEC CIK of Autolus Therapeutics? The SEC Central Index Key (CIK) for Autolus Therapeutics plc is 1730463. Its filings are on SEC EDGAR. How many shares does Autolus Therapeutics have outstanding? 266,162,540 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Autolus Therapeutics listed under? Our directory records Autolus Therapeutics plc under United Kingdom. What does Autolus Therapeutics do? Our directory classifies Autolus Therapeutics plc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Autolus Therapeutics? The ISIN recorded for Autolus Therapeutics plc is US05280R1005. Does aibio.space cover Autolus Therapeutics? aibio.space lists Autolus Therapeutics plc among 2,820 public biotech companies and publishes its news here as stories appear. Where is Autolus Therapeutics incorporated? SEC records list its state or country of incorporation as X0. Is Autolus Therapeutics profitable? Autolus Therapeutics plc reported a net loss of $287.5 million for the fiscal year ended Dec 31, 2025, and used $283.6 million of cash in operations, per its annual report to the SEC. How much does Autolus Therapeutics spend on research and development? $117.7 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Autolus Therapeutics have? $201.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Autolus Therapeutics (AUTL) stock news? Our latest story on Autolus Therapeutics, dated Aug 3, 2026: "Autolus issues first $75 million under up to $250 million Perceptive facility". Autolus issued an initial $75 million of notes to Perceptive Advisors on July 30, 2026 under a five-year, interest-only credit facility of up to $250 million. The company's outlook for cash into the second quarter of 2028 counts the first two tranches totaling $100 million. [Source](https://aibio.space/news/autolus-issues-first-75-million-under-up-250-million-perceptive/). What is Autolus Therapeutics's latest stock offering or financing news? Our latest financing story, dated Aug 3, 2026: "Autolus issues $75.0 million of notes under up to $250.0 million Perceptive facility". The senior secured notes mature July 30, 2031. Perceptive also received a warrant for up to 3,500,000 American Depositary Shares at $1.9314 each. [Source](https://aibio.space/news/autolus-issues-75-0-million-notes-under-up-250-0-million-perceptive/). ## Investor discussion: Autolus Therapeutics Members talk about Autolus Therapeutics (AUTL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Autolus Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-08-03 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1730463/000119312526329526/d156965d8k.htm) 2. 2026-04-29 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1730463/000119312526192362/d113906dex991.htm) 3. 2026-04-16 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000049/autl-20260414.htm) 4. 2025-12-02 Financings Reported a financing. SEC Form 8-K (Items 5.02,7.01). [Source](https://www.sec.gov/Archives/edgar/data/1730463/000173046325000095/autlex-991pr011225.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AUTL on TradingView](https://www.tradingview.com/symbols/NASDAQ-AUTL/). ## SEC filings and registration - **SEC name**: Autolus Therapeutics plc - **CIK**: 1730463 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: AUTL (Nasdaq) - **State or country of incorporation**: X0 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: THE MEDIAWORKS, LONDON, United Kingdom, W12 7FP - **Phone**: 44 20 3829 6230 - **Shares outstanding**: 266,162,540 as of 2026-08-10 (10-Q filed 2026-08-11) - **Former names**: Autolus Therapeutics Ltd ### Recent filings (8-K and 6-K are the company's own announcements) - [S-3](https://www.sec.gov/Archives/edgar/data/1730463/000119312526389586/d112040ds3.htm) filed 2026-09-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000123/autl-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000119/autl-20260811.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000112/autl-20260803.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1730463/000119312526329526/d156965d8k.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000072/autl-20260629.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000069/autl-20260605.htm) filed 2026-06-09 - [10-Q](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000065/autl-20260331.htm) filed 2026-05-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001730463), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Autolus Therapeutics plc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AUTL, recorded under United Kingdom. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Autolus Therapeutics plc - **Ticker**: AUTL - **Listing**: NASDAQ - **Country or territory**: United Kingdom - **Business scope**: Pharmaceuticals: Major - **ISIN**: US05280R1005 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-AUTL/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/autolus-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Autolus Therapeutics (AUTL) news: layoffs", 2026-10-31, https://aibio.space/companies/autolus-therapeutics/